M.D. Anderson Cancer Center
This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.
Primary Objective: To establish the safety of TGFBR2 KO CAR27/IL-15 NK cells in patients with R/R lymphomas and B-ALL through the following primary endpoints * To determine the recommended phase 2 dose (RP2D) of this treatment. * To define the dose-limiting toxicity (DLT) of this treatment. Secondary Objectives: 1. To observe and record anti-tumor activity through the following secondary endpoints: * Day+ 30 complete response (CR) rate. * Day +30 overall response rate (ORR). * Day 180 progression-free survival rate 2. To quantify the persistence of infused donor TGFBR2 KO CAR27/I…
Inclusion Criteria: 1. 18-75 years of age. 2. Diagnosis of relapsed B-NHL, HL, T-NHL, or B-ALL in refractory relapse, defined as: * B-NHL: Failure of \>/= 1 salvage line and failure of or ineligibility for CAR-T. * HL and T-NHL: Failure of \>/= 1 salvage line or prior SCT. * ALL: Active disease (\>5% of blasts or positive MRD at a level of \>0.1% measured by multiparameter flow cytometry) after ≥ 2 two lines of therapy. Patients with B-ALL must have either failed of or be ineligible for CAR-T cell therapy. Patients who have mutations for which there are FDA approved targeted therapi…
Given by IV
Given by IV
Given by IV
Arctuva estimate
Verify or correct the compensation shown for this listing.